8-KLeadership ChangesExhibits & Filings

Zoetis Inc. 8-K Report, Executive Changes (Jul 25, 2022)

Filed July 25, 2022For Securities:ZTS

Summary

Zoetis Inc. (ZTS) has announced a significant governance update with the appointment of Vanessa Broadhurst to its Board of Directors, effective July 25, 2022. This appointment increases the size of the Board from eleven to twelve members and sees Ms. Broadhurst joining the Quality and Innovation Committee. Ms. Broadhurst's appointment is a key development for investors, suggesting a continued focus on strengthening the board's expertise, particularly in areas relevant to product development and quality. As she is eligible for the company's standard non-employee director compensation, this move is not expected to introduce new or unusual compensation structures. The filing also confirms no related-party transactions involving Ms. Broadhurst that require disclosure, indicating a clean onboarding process.

Key Highlights

  • 1Vanessa Broadhurst appointed to Zoetis Inc. Board of Directors, effective July 25, 2022.
  • 2Board size increased from eleven to twelve members.
  • 3Ms. Broadhurst will serve on the Quality and Innovation Committee.
  • 4The appointment is not based on any third-party arrangements or reportable related-party transactions.
  • 5Ms. Broadhurst is eligible for the standard non-employee director compensation program.
  • 6A standard form of indemnification agreement was entered into with Ms. Broadhurst.
  • 7The company issued a press release on July 25, 2022, announcing the appointment.

Frequently Asked Questions

Vanessa Broadhurst has been appointed to the Board of Directors of Zoetis Inc. She will serve on the Board's Quality and Innovation Committee and her appointment increases the total number of directors from eleven to twelve.

No, Ms. Broadhurst is eligible for Zoetis's standard non-employee director compensation program. The filing also states there are no reportable related-party transactions between the company and Ms. Broadhurst.

Ms. Broadhurst's role on the Quality and Innovation Committee is likely to bring valuable expertise to Zoetis's product development, research, and quality assurance strategies, which are crucial for a pharmaceutical company focused on animal health.

The Board size was increased specifically to accommodate the appointment of Ms. Broadhurst, indicating the company's strategic decision to add her specific skills and experience to its governing body.